Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
cardonizumab + lenvatinib + SOX
- Development stage
- Unknown
- Modality
- Nucleic Acid-Directed Small Molecules → Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, Covalent Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Administration
- Intravenous, Oral
01
Overview
This is a combination therapy consisting of cardonizumab (also referred to as candenizumab in some sources), lenvatinib, and the SOX chemotherapy regimen. Cardonizumab is presumed to be an immune checkpoint inhibitor, likely a monoclonal antibody targeting PD-1 or CTLA-4 based on naming conventions and its use in immunotherapy combinations. Lenvatinib is a small molecule multi-targeted tyrosine kinase inhibitor that blocks VEGFR1-3, FGFR1-4, PDGFRα, RET, and KIT signaling pathways to inhibit tumor angiogenesis and proliferation. The SOX regimen consists of S-1 (an oral fluoropyrimidine derivative containing tegafur, gimeracil, and oteracil) plus oxaliplatin (a platinum-based chemotherapeutic). Both S-1 and oxaliplatin are cytotoxic agents commonly used in gastrointestinal cancers. This combination is being investigated for the treatment of HER2-negative advanced gastric or gastroesophageal junction adenocarcinoma[1][3]. The rationale for this combination lies in leveraging immune checkpoint blockade with antiangiogenic therapy and cytotoxic chemotherapy to enhance antitumor efficacy.
- Other names
- cardonizumab + lenvatinib + SOXcandenizumab + lenvatinib + SOX regimen
02
Targets
FGFR3 (Fibroblast growth factor receptor 3)FGFR4 (Fibroblast growth factor receptor 4)TS (Thymidylate synthase)VEGFR4 (Vascular endothelial growth factor Receptor-3)KIT (c-KIT proto-oncogene receptor tyrosine kinase)FGFR2 (Keratinocyte growth factor receptor)PDCD1 (Programmed cell death protein 1 receptor)PDGFRA (Platelet-derived growth factor receptor alpha)DNAVEGFR-1 (Vascular endothelial growth factor receptor 1)RET (Rearranged during transfection receptor tyrosine kinase)VEGFR2 (Vascular endothelial growth factor receptor 2)FGFR1 (Fibroblast growth factor receptor 1)
Beyond the preview
Go deeper on cardonizumab + lenvatinib + SOX.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on cardonizumab + lenvatinib + SOX.